Targeting the immune system as a therapeutic strategy in solid tumors has shown great efficacy in various tumor types. However the role and success of this approach in glioblastomas remain to be determined. Recent studies demonstrated that central nervous system is no longer considered as an immunoprivileged sanctuary with impressive immune response without blood brain barrier's disruption. Improving our understanding of immune privilege in the central nervous system could lead to better treatment strategies in gliobastomas. This review focuses on describing the immune system in the central nervous system and immuno-therapeutic strategies under development in glioblastomas.
Keywords: CNS; Glioblastoma; Glioblastome; Immune checkpoint; Immunotherapy; Immunothérapie; Inhibiteurs du point; SNC; de contrôle; immunitaire; inhibitors.
© 2018 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés.